NDA 018892 · Hospira
Sodium Phosphates In Plastic Container
Sodium Phosphate, Dibasic, Heptahydrate, Sodium Phosphate, Monobasic, Monohydrate · Intravenous
Last checked: Nov 20, 2026Latest source record: Nov 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1983
May 10, 1983
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
214
197 serious, 51 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 12, 2026.
INDICATIONS AND USAGE Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (Na + 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 10, 1983 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- SODIUM PHOSPHATES IN PLASTIC CONTAINER · SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 4.02GM/15ML; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 4.14GM/15ML (268MG/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Sodium Phosphates In Plastic Container" as an intervention, any sponsor and status, largest first.
Universiti Sains MalaysiaAcademic, hospital or other
NCT05772039 · 72 participants (planned) · Start Jan 18, 2022 · Primary completion Jul 15, 2023
Drug: Topical application of 38% Silver Diammine Fluoride Solution; Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish · For: Early Childhood Caries; Dental Caries in Children; Dental Caries Extending Into Dentin and 3 more
Sites: Lahore, Pakistan
Northside Hospital, Inc.Academic, hospital or other
NCT00787761 · 24 participants · Start Apr 2007 · Primary completion Jul 2010
Drug: anti-thymocyte globulin; busulfan and 4 more · For: Myeloproliferative Disorders; Kidney Cancer; Leukemia and 4 more
Sites: Atlanta, Georgia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthenia19
- diarrhoea19
- renal failure acute19
- nausea18
- constipation16
- dehydration14
- fall14
- pyrexia14
- vomiting14
- dizziness13
- dyspnoea13
- urinary tract infection13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 22 |
| 2007 | 19 |
| 2008 | 21 |
| 2009 | 28 |
| 2010 | 23 |
| 2011 | 14 |
| 2012 | 16 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 7 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 10 |
| 2023 | 5 |
| 2024 | 9 |
| 2025 | 9 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.